Analysis of the Bleeding and Thromboembolic Risk With Concomitant Use of Antiplatelet Treatment in the Amplify Trial

Cohen, Alan; Agnelli, Giancarlo; Büller, HR; Chaudhuri, Sayani; Gallus, Alexander; Raskob, Gary E.; Sanders, Philip; Thompson, Jonathon; Weitz, Juergen

doi:10.1016/j.cjca.2014.07.481

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Concomitant administration of these drugs did not appear to influence the rates of VTE or VTE-related death. 48 EINSTEIN DVT and PE study cohorts were used to compare the incidence of clinically relevant bleeding and major bleeding in patients with VTE receiving study anticoagulant therapy combined with either NSAID or aspirin compared with patients receiving anticoagulant therapy only: combined anticoagulant and NSAID or aspirin therapy was associated with an increased risk of clinically relevant bleeding.…”

Section: Antiplatelet Agents Nsaids Other Concomitant Medications mentioning

confidence: 99%

The Novel Oral Anticoagulants for Acute Venous Thromboembolism: Is Warfarin Dead?

Cohen

Granziera²,

Veronese

et al. 2017

Semin Respir Crit Care Med

View full text Add to dashboard Cite

The direct oral anticoagulants (DOACs) have been compared with parenteral anticoagulants and vitamin K antagonists (VKAs) for the treatment of venous thromboembolism (VTE) in several robust studies. DOACs have shown similar efficacy in preventing recurrent VTE and significant reductions in critical site (intracranial) bleeding, fatal bleeding, major and nonmajor bleeding. Warfarin and other VKAs are not dead as treatment modalities for VTE. A better way to describe the current situation is to use a boxing expression, "down but not out." VKAs and parenteral anticoagulants still have a role to play in the management of VTE in several clinical settings. In indications where DOACs can be used, VKAs should not, as the safety profile of VKAs is considerably worse than DOACs. Hence, guidelines are now recommending DOACs in preference to VKAs. In this article, we consider where DOACs are indicated, where there is growing evidence for use, where we have little evidence for use, and finally where there is no evidence for use and where they, thus, should not be used. We have included recommendations and examples of our own practice which may not be applicable to all settings.

show abstract

Section: Antiplatelet Agents Nsaids Other Concomitant Medications mentioning

confidence: 99%

The Novel Oral Anticoagulants for Acute Venous Thromboembolism: Is Warfarin Dead?

Cohen

Granziera²,

Veronese

et al. 2017

Semin Respir Crit Care Med

View full text Add to dashboard Cite

show abstract

Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of deep vein thrombosis

Wang

et al. 2023

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of pulmonary embolism

Wang

et al. 2023

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Analysis of the Bleeding and Thromboembolic Risk With Concomitant Use of Antiplatelet Treatment in the Amplify Trial

Cited by 3 publications

References 0 publications

The Novel Oral Anticoagulants for Acute Venous Thromboembolism: Is Warfarin Dead?

The Novel Oral Anticoagulants for Acute Venous Thromboembolism: Is Warfarin Dead?

Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of deep vein thrombosis

Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of pulmonary embolism

Contact Info

Product

Resources

About